Optiver Holding
ALDX icon

Optiver Holding’s Aldeyra Therapeutics ALDX Stock Holding History

Optiver Holding’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.72K Buy
4,566
+3,586
+366% +$15.7K ﹤0.01% 1287
2025
Q4 		$5.08K Hold
980
– – ﹤0.01% 1362
2025
Q3 		$5.12K Buy
+980
New +$5.11K ﹤0.01% 1720

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Optiver Holding's ALDX Position: Q1 2026 in Review

Optiver Holding increased its Aldeyra Therapeutics (ALDX) stake by 366% in Q1 2026, buying an estimated $15.7K and bringing the position to 4,566 shares worth $7.72K. The position accounts for ﹤0.01% of the portfolio, ranked #1287.

Optiver Holding first reported a position in ALDX in Q3 2025 and has held it in 3 quarters since. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

  • Optiver Holding held 4,566 shares of Aldeyra Therapeutics worth $7.72K as of Q1 2026.
  • Optiver Holding bought 3,586 Aldeyra Therapeutics shares in Q1 2026, an estimated $15.7K.
  • Aldeyra Therapeutics made up ﹤0.01% of Optiver Holding's portfolio in Q1 2026, its #1287 holding.
  • Optiver Holding first reported a position in Aldeyra Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on Optiver Holding's 13F filing for Q1 2026, filed 15 May 2026.